Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H.pylori infection. METHODS: Two hundred and four H.pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H.pylori eradication in Korea.

Original languageEnglish
Pages (from-to)140-143
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume73
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Lansoprazole
Amoxicillin
Helicobacter Infections
Korea
Helicobacter pylori
Group Psychotherapy
Pylorus
Therapeutics
Clarithromycin
Peptic Ulcer
Safety

Keywords

  • Amoxicillin/administration and dosage
  • Combination
  • Drug therapy
  • Helicobacter pylori/drug therapy
  • Proton pump inhibitors/administration and dosage

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{7f9bac50ecb54b47911358f8c73857c8,
title = "Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea",
abstract = "AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H.pylori infection. METHODS: Two hundred and four H.pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8{\%} in the triple therapy group and 78.4{\%} in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H.pylori eradication in Korea.",
keywords = "Amoxicillin/administration and dosage, Combination, Drug therapy, Helicobacter pylori/drug therapy, Proton pump inhibitors/administration and dosage",
author = "Kim, {Seung Young} and Jung, {Sung Woo} and Kim, {Jeong Han} and Koo, {Ja Seol} and Yim, {Hyung Joon} and Park, {Jong Jae} and Hoon-Jai Chun and Lee, {Sang Woo} and Choi, {Jai Hyun}",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1365-2125.2011.04048.x",
language = "English",
volume = "73",
pages = "140--143",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea

AU - Kim, Seung Young

AU - Jung, Sung Woo

AU - Kim, Jeong Han

AU - Koo, Ja Seol

AU - Yim, Hyung Joon

AU - Park, Jong Jae

AU - Chun, Hoon-Jai

AU - Lee, Sang Woo

AU - Choi, Jai Hyun

PY - 2012/1/1

Y1 - 2012/1/1

N2 - AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H.pylori infection. METHODS: Two hundred and four H.pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H.pylori eradication in Korea.

AB - AIM: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H.pylori infection. METHODS: Two hundred and four H.pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment. RESULTS: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002). CONCLUSIONS: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H.pylori eradication in Korea.

KW - Amoxicillin/administration and dosage

KW - Combination

KW - Drug therapy

KW - Helicobacter pylori/drug therapy

KW - Proton pump inhibitors/administration and dosage

UR - http://www.scopus.com/inward/record.url?scp=83155173136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83155173136&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2011.04048.x

DO - 10.1111/j.1365-2125.2011.04048.x

M3 - Article

C2 - 21689141

AN - SCOPUS:83155173136

VL - 73

SP - 140

EP - 143

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -